Clinical Research Headquarters
929 North Front Street
PPD is part of Thermo Fisher Scientific. As the world’s leader in serving science, our professionals develop critical solutions—and build rewarding careers. We offer services and products that help customers around the globe in laboratories and clinics, on production lines and out in the field.
We’re a driving force in the research, healthcare, industrial and applied markets, generating more $35 billion in annual revenue. No other company can match our range of customer touch points—technologically, geographically or commercially. We help customers in finding cures for cancer, protecting the environment, bringing medicines to market, making sure our food is safe and moving forward with thousands of important projects that improve millions of lives.
Stock Symbol: TMO
Stock Exchange: NYSE
Find PPD on social media:
Find PPD Careers on social media:
We All Have Our Why | PPD
444 articles about PPD
PPD, Inc., a leading global contract research organization, has been named to Forbes magazine’s 2020 list of America’s Best-in-State Employers for North Carolina.
PPD, Inc., a leading global contract research organization, reported its financial results for the second quarter ended June 30, 2020.
PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, today announced it has signed a new three-year agreement with Pfizer Inc. to provide drug development services to advance Pfizer’s portfolio. Under the terms of the agreement, Pfizer has the right to extend the term for additional two-year periods. Financial details of the agreement were not disclosed. The agreement builds on the companies’ e
PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, will host a conference call on Wednesday, Aug. 5, 2020, at 8:30 a.m. (U.S. Eastern Time) to discuss its second quarter 2020 financial results.
PPD, Inc. (Nasdaq: PPD ) has expanded its laboratory test portfolio by adding five new molecular, serology and functional assays designed expressly for COVID-19 vaccine and therapy development programs. These assays have been developed by PPD ® Laboratories’ bioanalytical, biomarker and vaccines sciences labs to run on multiple assay platforms and are compatible with high-throughput liquid handling so they can support
PPD, Inc., a leading global contract research organization, announced that Jaguar Holding Company II and PPD Development, L.P., both indirect wholly owned subsidiaries of the Company, successfully upsized and finalized the terms of the Co-Issuers’ offering of $500 million aggregate principal amount of 4.625% senior notes due 2025 and $700 million aggregate principal amount 5.000% senior notes due 2028.
PPD, Inc., a leading global contract research organization, announced that it intends to offer $700 million in aggregate principal amount of senior notes, subject to market and other conditions.
PPD, Inc. has been recognized for excellence in clinical research for the ninth consecutive year by pharmaceutical and biotech professionals surveyed for Life Science Leader magazine’s 2020 CRO Leadership Awards.
PPD, Inc., a leading global contract research organization, reported its financial results for the first quarter ended March 31, 2020.
PPD Extends Digital Clinical Trial Capabilities to Support Biopharma Companies’ Research Continuity and Patient Safety during COVID-19 Pandemic
PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, has extended its digital clinical trial solutions to support biopharma companies’ research continuity initiatives and to help ensure patient safety as part of its integrated response to the COVID-19 pandemic. PPD’s extensive, flexible suite of digital trial solutions – from electronic patient consent to telehealth to hybrid and fully dece
PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today announced it will release its first quarter 2020 results after market close on Wednesday, May 6, 2020.
PPD Announces Cancellation of Fireside Chat and Webcast at the Barclays Global Healthcare Conference 2020
PPD, Inc. (Nasdaq:PPD) today announced the cancellation of its fireside chat and related webcast at the Barclays Global Healthcare Conference, previously scheduled for Wednesday, March 11, at 11:45 a.m. (U.S. Eastern Time), as a result of the conference switching to a virtual format. About PPD PPD is a leading global contract research organization providing comprehensive, integrated drug development, labora
PPD, Inc., a leading global contract research organization, announced that its management team will participate in the Barclays Global Healthcare Conference on March 11, 2020, at the Loews Miami Beach Hotel in Miami Beach, Florida.
PPD, Inc. (NASDAQ: PPD), a leading global contract research organization, today reported its financial results for the fourth quarter and full year ended December 31, 2019.
Feb. 25, 2020 14:15 UTC Honored by Training magazine for ninth consecutive year WILMINGTON, N.C.--( BUSINESS WIRE )-- PPD, Inc. (Nasdaq:PPD), has been named to Training magazine’s 2020 Training Top 125 list , recognizing organizations that excel at employee training and development. “PPD empowers our greatest asset, our talented and committed employees, to achieve a culture of high performance that enables exceptional service delivery for our pharmaceutical and bi
Feb. 20, 2020 14:00 UTC WILMINGTON, N.C.--( BUSINESS WIRE )-- PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today announced it will release its fourth quarter and full year 2019 results and issue full year 2020 guidance after market close on Wednesday, March 4, 2020. The earnings release and accompanying financial information will be available on the investors section of PPD’s website at https://investors.ppdi.com . The release will be followed by a con
PPD, Inc. announced the pricing of its initial public offering of 60 million shares of its common stock at $27.00 per share.
PPD, Inc. today announced the launch of its initial public offering of 60 million shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission (SEC).
Enhancing Drug Development for International Pharma Companies and Chinese Biotechs
The recognition from PM360 – a leading magazine for marketing decision-makers in the pharmaceutical, biotech, medical device and diagnostics industries – appears in its 8th Annual Innovations Issue, a guide to the year’s most compelling advancements in the life sciences.